ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Immutep Expands Part B of TACTI-002 Study americanpharmaceuticalreview
March 10, 2021Immutep has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients ...
Pharma Sources Insight January 2025
